BofA raised the firm’s price target on Syndax (SNDX) to $26 from $25 and keeps a Buy rating on the shares. The firm thought “there was a lot to like about Syndax’s 1Q update,” the analyst tells investors. The firm notes that its increased its price target to account for Revuforj’s better than expected early ramp.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Promising Growth and Strategic Positioning Drive Buy Rating for Syndax Pharmaceuticals
- Syndax Pharmaceuticals Reports Strong Q1 2025 Results
- Syndax reports Q1 EPS (98c), consensus ($1.27)
- SNDX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Actinium’s Actimab-A shows antileukemic activity in AML models